Table 1 Demographic and clinical characteristics of the breast cancer survivors during endocrine therapy
Characteristics | Overall (n = 89) n (%) |
|---|---|
Age (years) – median (p25-p75) | 65 (58.5–69.5) |
 < 60 | 25 (28.1) |
 ≥ 60 | 64 (71.9) |
Marital Status | |
  Single/ Divorced/Separated/Widow | 50 (56.2) |
  Married | 39 (43.8) |
Partner | |
  No | 22 (24.7) |
  Yes | 67 (75.3) |
Educational Level | |
  Below high school | 61 (68.5) |
  High school or higher education | 28 (31.5) |
Income (minimum wage) | |
  < 3 | 53 (59.6) |
  ≥ 3 | 36 (40.4) |
Work activity | |
  Active | 22 (24.7) |
  Inactive | 67 (75.3) |
Surgery | |
  Breast-conserving surgery | 51 (57.3) |
  Mastectomy | 38 (42.7) |
Prior Radiotherapy | |
  No | 14 (15.7) |
  Yes | 75 (84.3) |
Prior Chemotherapy | |
  No | 21 (23.6) |
  Yes | 68 (76.4) |
Chemotherapy Regimen | |
  Adjuvant | 53 (77.9) |
  Neoadjuvant | 15 (22.1) |
Prior Tamoxifen | |
  No | 49 (55.1) |
  Yes | 40 (44.9) |
Tumoral Subtype | |
  Ductal | 86 (96.6) |
  Lobular | 3 (3.4) |
Clinical Stage | |
  I | 26 (29.2) |
  II | 48 (53.9) |
  III | 13 (14.6) |
  NR | 2 (2.2) |
Tumor Grade | |
  G1 | 14 (15.7) |
  G2 | 66 (74.2) |
  G3 | 5 (5.6) |
  NR | 4 (4.5) |
Molecular Subtype | |
  ER + and/or PR + , HER2- and Ki-67 < 14% | 17 (19.1) |
  ER + and/or PR + , HER2- and Ki-67 ≥ 14% | 37 (41.6) |
  ER + and/or PR + , HER2 +  | 29 (32.6) |
  NR | 6 (6.7) |
Months since start on AI | 29.5 (18.1–41.8) |
Years since diagnosis | 4 (2—5) |
Years since last menstrual period | 16 (8—20) |